Next Article in Journal
The Impact of Human Lipoaspirate and Adipose Tissue-Derived Stem Cells Contact Culture on Breast Cancer Cells: Implications in Breast Reconstruction
Next Article in Special Issue
Serum APOA4 Pharmacodynamically Represents Administered Recombinant Human Hepatocyte Growth Factor (E3112)
Previous Article in Journal
Role of PD-L1 in Gut Mucosa Tolerance and Chronic Inflammation
Previous Article in Special Issue
The Potential Role of Hepatocyte Growth Factor in Degenerative Disorders of the Synovial Joint and Spine
Review

Targeting HGF/c-MET Axis in Pancreatic Cancer

1
Pancreatic Research Group, South Western Sydney Clinical School, Faculty of Medicine and Ingham Institute for Applied Medical Research, Liverpool, NSW 2170, Australia
2
Faculty of Medicine, The University of New South Wales, Sydney, NSW 2052, Australia
*
Author to whom correspondence should be addressed.
These authors contribute equally to this work.
Int. J. Mol. Sci. 2020, 21(23), 9170; https://doi.org/10.3390/ijms21239170
Received: 30 October 2020 / Revised: 27 November 2020 / Accepted: 28 November 2020 / Published: 1 December 2020
(This article belongs to the Special Issue Hepatocyte Growth Factor (HGF), II)
Pancreatic cancer (pancreatic ductal adenocarcinoma (PDAC/PC)) has been an aggressive disease that is associated with early metastases. It is characterized by dense and collagenous desmoplasia/stroma, predominantly produced by pancreatic stellate cells (PSCs). PSCs interact with cancer cells as well as other stromal cells, facilitating disease progression. A candidate growth factor pathway that may mediate this interaction is the hepatocyte growth factor (HGF)/c-MET pathway. HGF is produced by PSCs and its receptor c-MET is expressed on pancreatic cancer cells and endothelial cells. The current review discusses the role of the MET/HGF axis in tumour progression and dissemination of pancreatic cancer. Therapeutic approaches that were developed targeting either the ligand (HGF) or the receptor (c-MET) have not been shown to translate well into clinical settings. We discuss a two-pronged approach of targeting both the components of this pathway to interrupt the stromal–tumour interactions, which may represent a potential therapeutic strategy to improve outcomes in PC. View Full-Text
Keywords: HGF-c-MET; Pancreatic Cancer; Stromal-tumour interactions HGF-c-MET; Pancreatic Cancer; Stromal-tumour interactions
Show Figures

Figure 1

MDPI and ACS Style

Pothula, S.P.; Xu, Z.; Goldstein, D.; Pirola, R.C.; Wilson, J.S.; Apte, M.V. Targeting HGF/c-MET Axis in Pancreatic Cancer. Int. J. Mol. Sci. 2020, 21, 9170. https://doi.org/10.3390/ijms21239170

AMA Style

Pothula SP, Xu Z, Goldstein D, Pirola RC, Wilson JS, Apte MV. Targeting HGF/c-MET Axis in Pancreatic Cancer. International Journal of Molecular Sciences. 2020; 21(23):9170. https://doi.org/10.3390/ijms21239170

Chicago/Turabian Style

Pothula, Srinivasa P., Zhihong Xu, David Goldstein, Romano C. Pirola, Jeremy S. Wilson, and Minoti V. Apte. 2020. "Targeting HGF/c-MET Axis in Pancreatic Cancer" International Journal of Molecular Sciences 21, no. 23: 9170. https://doi.org/10.3390/ijms21239170

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop